Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$44.31 -0.2%	$36.67	$21.72 ▼ $45.18	$8.40B	1.1	2.47 million shs	338,660 shs
BPMC Blueprint Medicines	$128.23 0.0%	$107.53	$73.04 ▼ $128.45	$8.28B	0.84	1.28 million shs	500,109 shs
VCEL Vericel	$41.76 -0.3%	$41.50	$37.39 ▼ $63.00	$2.10B	1.33	466,637 shs	17,260 shs
VRNA Verona Pharma PLC American Depositary Share	$95.27 +0.2%	$76.98	$14.14 ▼ $99.01	$8.13B	0.21	1.31 million shs	173,047 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	-0.16%	+10.95%	+33.11%	+21.92%	+89.82%
BPMC Blueprint Medicines	-0.01%	+0.10%	+26.35%	+42.93%	+20.37%
VCEL Vericel	-3.37%	+0.24%	+2.35%	-9.09%	-6.71%
VRNA Verona Pharma PLC American Depositary Share	-2.17%	+4.61%	+26.71%	+47.43%	+532.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.5314 of 5 stars	4.5	2.0	3.9	1.7	3.3	0.6
BPMC Blueprint Medicines	1.2169 of 5 stars	2.1	2.0	0.0	2.6	0.8	0.6
VCEL Vericel	2.4985 of 5 stars	3.5	1.0	0.0	1.7	0.8	1.9
VRNA Verona Pharma PLC American Depositary Share	2.4346 of 5 stars	2.5	3.0	0.0	3.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.92	Moderate Buy	$57.42	29.59% Upside
BPMC Blueprint Medicines	2.27	Hold	$128.06	-0.13% Downside
VCEL Vericel	3.00	Buy	$61.14	46.41% Upside
VRNA Verona Pharma PLC American Depositary Share	3.00	Buy	$101.10	6.12% Upside

Current Analyst Ratings Breakdown

Latest VCEL, BPMC, BBIO, and VRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	BBIO BridgeBio Pharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $54.00
6/23/2025	VRNA Verona Pharma PLC American Depositary Share	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$76.00 ➝ $160.00
6/20/2025	VRNA Verona Pharma PLC American Depositary Share	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$107.00 ➝ $138.00
6/18/2025	VRNA Verona Pharma PLC American Depositary Share	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$92.00 ➝ $116.00
6/17/2025	BBIO BridgeBio Pharma	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$49.00
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00
6/16/2025	VCEL Vericel	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$67.00
6/11/2025	VRNA Verona Pharma PLC American Depositary Share	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $100.00
6/11/2025	VRNA Verona Pharma PLC American Depositary Share	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$95.00 ➝ $110.00
6/9/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$53.00 ➝ $56.00
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00

(Data available from 6/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$221.90M	37.91	N/A	N/A	($7.71) per share	-5.75
BPMC Blueprint Medicines	$508.82M	16.27	N/A	N/A	$4.70 per share	27.28
VCEL Vericel	$238.54M	8.81	$0.30 per share	138.69	$5.92 per share	7.05
VRNA Verona Pharma PLC American Depositary Share	$42.28M	191.82	N/A	N/A	$2.56 per share	37.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-524.25%	N/A	-94.43%	7/30/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	197.27	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
VCEL Vericel	$10.36M	$0.03	1,392.40	94.91	N/A	1.25%	1.09%	0.73%	7/30/2025 (Estimated)
VRNA Verona Pharma PLC American Depositary Share	-$173.42M	-$2.00	N/A	3,175.67	N/A	N/A	-69.65%	-28.00%	8/6/2025 (Estimated)

Latest VCEL, BPMC, BBIO, and VRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	VCEL Vericel	-$0.09	-$0.23	-$0.14	-$0.23	$53.86 million	$52.60 million
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million
4/29/2025	Q1 2025	VRNA Verona Pharma PLC American Depositary Share	-$0.22	$0.27	+$0.49	-$0.16	$41.47 million	$98.65 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma PLC American Depositary Share	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.57	4.54
BPMC Blueprint Medicines	1.01	2.80	2.75
VCEL Vericel	N/A	5.01	4.58
VRNA Verona Pharma PLC American Depositary Share	1.07	8.86	8.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
BPMC Blueprint Medicines	N/A
VCEL Vericel	N/A
VRNA Verona Pharma PLC American Depositary Share	85.88%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
BPMC Blueprint Medicines	4.21%
VCEL Vericel	5.20%
VRNA Verona Pharma PLC American Depositary Share	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	189.88 million	155.32 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
VCEL Vericel	300	50.34 million	47.73 million	Optionable
VRNA Verona Pharma PLC American Depositary Share	30	85.13 million	81.05 million	Optionable

VCEL, BPMC, BBIO, and VRNA Headlines

Recent News About These Companies

SG Americas Securities LLC Takes Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

June 26 at 3:20 AM | marketbeat.com

HBK Sorce Advisory LLC Sells 3,800 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

June 25 at 7:35 AM | marketbeat.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Reaches New 52-Week High on Analyst Upgrade

June 25 at 2:19 AM | americanbankingnews.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Hits New 52-Week High After Analyst Upgrade

June 23 at 2:11 PM | marketbeat.com

Piper Sandler Forecasts Strong Price Appreciation for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Stock

June 23 at 12:25 PM | marketbeat.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Shares Sold by PFG Investments LLC

June 22, 2025 | marketbeat.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Price Target Raised to $138.00 at Wells Fargo & Company

June 21, 2025 | americanbankingnews.com

Roth Capital Hikes Verona Pharma’s (VRNA) Price Target to $116 On COPD Market Prospects

June 20, 2025 | msn.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given New $138.00 Price Target at Wells Fargo & Company

June 20, 2025 | marketbeat.com

Roth Capital Reiterates Buy Rating for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

June 20, 2025 | americanbankingnews.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) General Counsel Andrew Fisher Sells 80,000 Shares of Stock

June 19, 2025 | insidertrades.com

Mission Wealth Management LP Purchases New Stake in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

June 19, 2025 | marketbeat.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) General Counsel Sells $922,400.00 in Stock

June 18, 2025 | marketbeat.com

Verona Pharma: An Impressive Initial Launch

June 18, 2025 | seekingalpha.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Receives "Buy" Rating from Roth Capital

June 18, 2025 | marketbeat.com

Traders Purchase Large Volume of Verona Pharma Put Options (NASDAQ:VRNA)

June 17, 2025 | americanbankingnews.com

Verona Pharma (NASDAQ:VRNA) Hits New 12-Month High - What's Next?

June 16, 2025 | marketbeat.com

Traders Purchase High Volume of Verona Pharma Put Options (NASDAQ:VRNA)

June 16, 2025 | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 400,000 Shares

June 16, 2025 | americanbankingnews.com

Verona Pharma plc (NASDAQ:VRNA) CFO Sells $4,560,000.00 in Stock

June 16, 2025 | americanbankingnews.com

Jefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre Launch

June 14, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL, BPMC, BBIO, and VRNA Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$44.30 -0.08 (-0.17%)

As of 10:55 AM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Blueprint Medicines NASDAQ:BPMC

$128.22 -0.03 (-0.02%)

As of 10:55 AM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Vericel NASDAQ:VCEL

$41.76 -0.12 (-0.29%)

As of 10:55 AM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Verona Pharma PLC American Depositary Share NASDAQ:VRNA

$95.27 +0.16 (+0.17%)

As of 10:54 AM Eastern

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time